PureTech Health (LON:PRTC) Shares Up 14.2% - What's Next?

Key Points

• PureTech Health shares surged by 14.2%, closing at GBX 121.50 ($1.64) after trading volume increased by 1,053% compared to the average daily share volume.
• The company's market capitalization stands at £293.65 million, with a debt-to-equity ratio of 45.82 and a high price-to-earnings ratio of 714.71.
• Insider Bharatt Chowrira purchased 167,739 shares at an average cost of GBX 1 each, contributing to insider ownership of 13.13% in the company.

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price traded up 14.2% during trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares traded hands during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Performance

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a market cap of £302.59 million, a price-to-earnings ratio of 736.47 and a beta of 1.02. The firm has a fifty day moving average of GBX 129.31 and a 200 day moving average of GBX 129.65.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira bought 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is currently owned by company insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.